Experts in the field of CLL/SLL discussed the role of BTK inhibitors and degraders in R/R CLL/SLL during an OncLive Scientific Interchange and Workshop.
Next-Generation Decisions in CLL: Redefining BTK Inhibitors Across the Frontline and Relapsed Settings
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
Five Under 5: Top Oncology Videos for the Week of 1/25
5